We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.
- Authors
Strati, Paolo; Fowler, Nathan; Pina-Oviedo, Sergio; Medeiros, L. Jeffrey; Overman, Michael J.; Romaguera, Jorge E.; Nastoupil, Loretta; Wang, Michael; Hagemeister, Fredrick B.; Rodriguez, Alma; Oki, Yasuhiro; Westin, Jason; Turturro, Francesco; Neelapu, Sattva S.; Fayad, Luis
- Abstract
<bold>Background: </bold>The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial.<bold>Patients and Methods: </bold>This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval.<bold>Results: </bold>The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph >4 node sites and presence of B symptoms. Three patients later progressed to diffuse large B cell lymphoma, all had baseline elevated serum lactate dehydrogenase level and high International Prognostic Index score. Median overall survival has not been reached. All 4 patients who later developed acute myeloid leukemia were older than 60 years at the time of start of therapy.<bold>Conclusion: </bold>R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
- Subjects
ANTINEOPLASTIC agents; LYMPHOMAS; PROGNOSIS; SURVIVAL analysis (Biometry); PHARMACODYNAMICS
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2018, Vol 18, Issue 1, pe103
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2017.11.001